Why Tenet Healthcare (THC) is a Top Growth Stock for the Long-Term

Tenet Healthcare holds a Zacks Rank #2 (Buy), VGM Score of A and Growth Style Score of B, supported by projected fiscal-year earnings growth of 25.4%. Nine analysts raised fiscal 2026 estimates over the past 60 days, lifting the consensus EPS forecast by $3.43 to $21.04; Tenet has also delivered an average earnings surprise of 22.7%. The article presents a constructive long-term growth case, though it is primarily ratings and estimate-revision commentary rather than a new company operating update.

Analysis

This is not a fresh fundamental catalyst; it is a promotional framing of already-public estimate revisions. The actionable question is whether the higher earnings base reflects durable ambulatory-surgery-center (ASC) mix, favorable payer rates, and hospital labor normalization rather than a transient utilization or acuity tailwind. THC's ASC exposure through USPI should produce structurally better margins and less reimbursement volatility than hospital-heavy peers such as HCA and CYH, but that advantage is likely increasingly recognized in valuation.

Over the next 1-3 months, the key catalyst is the next print: sustained same-facility revenue growth plus stable labor costs would force further upward revisions and support multiple expansion versus HCA. Conversely, a miss in USPI case volumes, adverse commercial-rate commentary, or higher bad-debt expense would matter more than a modest hospital-volume shortfall because the market is underwriting mix-driven earnings quality. Watch Medicare outpatient/ASC reimbursement proposals and California/Florida wage trends as leading indicators.

Contrarian view: estimate momentum alone is insufficient after repeated upside surprises; it can signal that consensus remains stale, but also that expectations are becoming difficult to beat. NNOX is not economically connected to the THC thesis despite appearing in the article's promotional material; no read-through should be inferred. The cleaner relative trade is THC versus lower-quality hospital operators, not a broad healthcare-beta purchase.

Key Decisions for Investors

• Maintain or initiate a 3-6 month long THC / short CYH pair, sized beta-neutral. THC offers superior ASC exposure and balance-sheet flexibility; CYH is more exposed to leveraged hospital-operator downside. Reassess if THC's next-quarter USPI revenue or adjusted EBITDA growth decelerates materially while CYH demonstrates sustained deleveraging.
• For directional exposure, buy THC only on post-earnings confirmation or a 5-8% pullback rather than chase rating-driven strength. Target a 10-15% upside over 6 months from another earnings-guide raise; risk-limit at a guidance cut or evidence that labor and bad-debt costs are reaccelerating.
• Monitor the next Medicare outpatient/ASC proposed rule and THC's same-facility ASC case-volume disclosure as 1-3 month catalysts. A negative reimbursement surprise or ASC volume miss is the thesis falsifier and warrants reducing the position.
• Do not trade NNOX from this item; its mention is promotional and provides no operational, customer, supplier, or valuation linkage to THC.